Results 1 to 10 of about 10,001 (127)

Pediatric immune myelofibrosis (PedIMF) as a novel and distinct clinical pathological entity

Frontiers in Pediatrics, 2022
Myelofibrosis is a rare myeloproliferative disorder. The detailed descriptions of myelofibrosis in children and adolescents is limited to a few case series and case reports describing fewer than 100 patients, thus suggesting the extreme rarity of this ...
Fabiola Guerra, Fabiola Guerra, Vincenzo L’Imperio, Sonia Bonanomi, Marco Spinelli, Tiziana Angela Coliva, Fabiola Dell’Acqua, Giulia Maria Ferrari, Paola Corti, Adriana Balduzzi, Andrea Biondi, Fabio Pagni, Francesco Saettini   +12 more
doaj   +1 more source

VEGFA rs3025020 Polymorphism Contributes to CALR-Mutation Susceptibility and Is Associated with Low Risk of Deep Vein Thrombosis in Primary Myelofibrosis

TH Open, 2021
Background Single nucleotide polymorphisms (SNPs) in vascular endothelial growth factor A (VEGFA) are associated with susceptibility to several diseases including cancer.
Laura Villani, Vittorio Rosti, Margherita Massa, Rita Campanelli, Paolo Catarsi, Adriana Carolei, Carlotta Abbà, Annalisa de Silvstri, Robert Peter Gale, Giovanni Barosi   +9 more
doaj   +1 more source

Targeted sequencing of candidate gene regions for myelofibrosis in dogs

Journal of Veterinary Internal Medicine, 2022
Background Myelofibrosis often lacks an identifiable cause in dogs. In humans, most primary myelofibrosis cases develop secondary to driver mutations in JAK2, CALR, or MPL.
Amelia G. Campbell, Davis M. Seelig, Joan D. Beckman, Katie M. Minor, Daniel A. Heinrich, Steven G. Friedenberg, Jaime F. Modiano, Eva Furrow   +7 more
doaj   +1 more source

Elevated plasma EDA fibronectin in primary myelofibrosis is determined by high allele burden of JAK2V617F mutation and strongly predicts splenomegaly progression

Frontiers in Oncology, 2022
In primary myelofibrosis, extra-domain A fibronectin (EDA-FN), the result of alternative splicing of FN gene, sustains megakaryocyte proliferation and confers a pro-inflammatory phenotype to bone marrow cell niches. In this work we assessed the levels of
Alessandro Malara, Cristian Gruppi, Margherita Massa, Maria Enrica Tira, Vittorio Rosti, Alessandra Balduini, Giovanni Barosi   +6 more
doaj   +1 more source

Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial

HemaSphere, 2021
Myelofibrosis symptoms compromise health-related quality of life (HRQoL). Ruxolitinib can reduce myelofibrosis symptom severity, but many patients discontinue ruxolitinib due to loss of response or unacceptable toxicity.
Claire N. Harrison, Nicolaas Schaap, Alessandro M. Vannucchi, Jean-Jacques Kiladjian, Eric Jourdan, Richard T. Silver, Harry C. Schouten, Francesco Passamonti, Sonja Zweegman, Moshe Talpaz, Srdan Verstovsek, Derek Tang, Pranav Abraham, Jennifer Lord-Bessen, Shelonitda Rose, Shien Guo, Weiqin Liao, Ruben A. Mesa   +17 more
doaj   +1 more source

Advances in myelofibrosis: a clinical case approach

Haematologica, 2013
Primary myelofibrosis is a member of the myeloproliferative neoplasms, a diverse group of bone marrow malignancies. Symptoms of myelofibrosis, particularly those associated with splenomegaly (abdominal distention and pain, early satiety, dyspnea, and ...
John O. Mascarenhas, Attilio Orazi, Kapil N. Bhalla, Richard E. Champlin, Claire Harrison, Ronald Hoffman   +5 more
doaj   +1 more source

Comparison of different criteria for the diagnosis of primary myelofibrosis reveals limited clinical utility for measurement of serum lactate dehydrogenase

Haematologica, 2010
Primary myelofibrosis shows histological and pathogenetic overlap with essential thrombocythemia and polycythemia vera. Several diagnostic classifications have been proposed for primary myelofibrosis, although little is known about their clinical utility.
Philip A. Beer, Peter J. Campbell, Anthony R. Green   +2 more
doaj   +1 more source

Tetraspanin CD9 participates in dysmegakaryopoiesis and stromal interactions in primary myelofibrosis

Haematologica, 2015
Primary myelofibrosis is characterized by clonal myeloproliferation, dysmegakaryopoiesis, extramedullary hematopoiesis associated with myelofibrosis and altered stroma in the bone marrow and spleen.
Christophe Desterke, Christophe Martinaud, Bernadette Guerton, Lisa Pieri, Costanza Bogani, Denis Clay, Frederic Torossian, Jean-Jacques Lataillade, Hans C. Hasselbach, Heinz Gisslinger, Jean-Loup Demory, Brigitte Dupriez, Claude Boucheix, Eric Rubinstein, Sophie Amsellem, Alessandro M. Vannucchi, Marie-Caroline Le Bousse-Kerdilès   +16 more
doaj   +1 more source

Transcriptional profiling of whole blood identifies a unique 5-gene signature for myelofibrosis and imminent myelofibrosis transformation. [PDF]

PLoS ONE, 2014
Identifying a distinct gene signature for myelofibrosis may yield novel information of the genes, which are responsible for progression of essential thrombocythemia and polycythemia vera towards myelofibrosis.
Hans Carl Hasselbalch, Vibe Skov, Thomas Stauffer Larsen, Mads Thomassen, Caroline Hasselbalch Riley, Morten K Jensen, Ole Weis Bjerrum, Torben A Kruse   +7 more
doaj   +1 more source

TGF-β signaling in myeloproliferative neoplasms contributes to myelofibrosis without disrupting the hematopoietic niche

The Journal of Clinical Investigation, 2022
Myeloproliferative neoplasms (MPNs) are associated with significant alterations in the bone marrow microenvironment that include decreased expression of key niche factors and myelofibrosis. Here, we explored the contribution of TGF-β to these alterations
Juo-Chin Yao, Karolyn A. Oetjen, Tianjiao Wang, Haoliang Xu, Grazia Abou-Ezzi, Joseph R. Krambs, Salil Uttarwar, Eric J. Duncavage, Daniel C. Link   +8 more
doaj   +1 more source